WO1993000427A3 - Neurite growth regulatory factors - Google Patents

Neurite growth regulatory factors Download PDF

Info

Publication number
WO1993000427A3
WO1993000427A3 PCT/EP1992/001384 EP9201384W WO9300427A3 WO 1993000427 A3 WO1993000427 A3 WO 1993000427A3 EP 9201384 W EP9201384 W EP 9201384W WO 9300427 A3 WO9300427 A3 WO 9300427A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
metalloproteases
treatment
myelin associated
malignant tumors
Prior art date
Application number
PCT/EP1992/001384
Other languages
French (fr)
Other versions
WO1993000427A2 (en
Inventor
Martin E Schwab
Pierenrico W Caroni
Paolo A Paganetti
Original Assignee
Canton Zurich Erziehungsdirekt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/719,692 external-priority patent/US5250414A/en
Application filed by Canton Zurich Erziehungsdirekt filed Critical Canton Zurich Erziehungsdirekt
Publication of WO1993000427A2 publication Critical patent/WO1993000427A2/en
Publication of WO1993000427A3 publication Critical patent/WO1993000427A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to genes and their encoded proteins which regulate neurite growth and the diagnostic and therapeutic use of such proteins (termed herein neurite growth regulatory factors). The proteins of the present invention include central nervous system myelin associated proteins and metalloproteases associated with glioblastoma cells and other malignant tumors which can metastasize to the brain. The CNS myelin associated proteins inhibit neurite outgrowth in nerve cells and neuroblastoma cells, and can also inhibit fibroblast spreading. Such inhibitory proteins include a 35,000 dalton and a 250,000 dalton molecular weight protein and analogs, derivatives, and fragments thereof. The CNS myelin associated inhibitory proteins may be used in the treatment of malignant tumors. The metalloproteases of the invention have value in the treatment of nerve damage and of degenerative disorders of the nervous system. The present invention is also directed to inhibitors of the metalloproteases. Such inhibitors in combination with the CNS myelin associated inhibitory proteins can be used in the treatment of malignant tumors.
PCT/EP1992/001384 1991-06-24 1992-06-19 Neurite growth regulatory factors WO1993000427A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/719,692 US5250414A (en) 1988-11-04 1991-06-24 Diagnostic methods using neurite growth regulatory factors
US719,692 1991-06-24

Publications (2)

Publication Number Publication Date
WO1993000427A2 WO1993000427A2 (en) 1993-01-07
WO1993000427A3 true WO1993000427A3 (en) 1993-04-29

Family

ID=24891002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1992/001384 WO1993000427A2 (en) 1991-06-24 1992-06-19 Neurite growth regulatory factors

Country Status (2)

Country Link
AU (1) AU2152092A (en)
WO (1) WO1993000427A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5891394A (en) * 1993-02-11 1994-08-29 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
HUP9900060A3 (en) * 1995-04-19 2001-08-28 Acorda Therapeutics New York Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5717092A (en) * 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CN1721444A (en) 1998-11-06 2006-01-18 苏黎世大学 Nucleotide and protein sequences of Nogo genes and methods based thereon
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000060064A1 (en) * 1999-04-01 2000-10-12 The Procter & Gamble Company A purification process for a calcium binding type enzyme, such as a metalloprotease, using a calcium free buffer
AU4216200A (en) * 1999-04-08 2000-10-23 Chiron Corporation Novel protein associated with cell stress response
US7186530B1 (en) 2000-04-07 2007-03-06 Chiron Corporation Protein associated with cell stress response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0046523A1 (en) * 1980-08-26 1982-03-03 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Nondenaturing zwitterionic detergents for membrane biochemistry
WO1990005191A1 (en) * 1988-11-04 1990-05-17 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0046523A1 (en) * 1980-08-26 1982-03-03 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Nondenaturing zwitterionic detergents for membrane biochemistry
WO1990005191A1 (en) * 1988-11-04 1990-05-17 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Experientia, vol. 46, March 1990, (Basel, CH) P.A. Paganetti et al.: "Glioblastoma infiltration into CNS tissue in vitro: the role of a metalloprotease", see abstract, & 22nd Annual Meeting of the Swiss Societies for Experimental Biology, March 15/16, 1990, Z}rich *
EXPERIMENTAL NEUROLOGY vol. 115, no. 1, January 1992, NEW YORK, US pages 189 - 192 D.S. CADELLI ET AL. 'Oligodendrocyte- and Myelin-Associated Inhibitors of Neurite Outgrowth: Their Involvement in the Lack of CNS Regeneration' *
J. CELL BIOL. vol. 107, no. 6, December 1988, NEW YORK, US pages 2281 - 2291 P. A. PAGANETTI ET AL. 'Glioblastoma Infiltration into Central Nervous System Tissue in Vitro: Involvement of a Metalloprotease' cited in the application *
J. Cell Biol., vol. 107, no. 6, December 1988 (New York, US) P.A. Paganetti et al.: "Glioblastoma infiltration into central nervous system tissue in vitro: involvement of a metalloprotease", pages 2281-2291, see abstract; page 2282, right-hand column, paragraphs 1-2 (cited in the application) *
J. CELL. BIOL. vol. 106, no. 4, April 1988, NEW YORK, US P. CARONI & M.E. SCHWAB 'Two Membrane Protein Fractions from Rat Central Myelin with Inhibitory Properties for Neurite Growth and Fibroblast Spreading' cited in the application *

Also Published As

Publication number Publication date
AU2152092A (en) 1993-01-25
WO1993000427A2 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
AU7435494A (en) Neurite growth regulatory factors
MX9604985A (en) Cardiotrophin and uses therefor.
NO991951L (en) Tienopyrimidines with phosphodiesterase V inhibitory effect
WO1993000427A3 (en) Neurite growth regulatory factors
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
CA2120303A1 (en) Cyclic adhesion inhibitors
IL111078A0 (en) Inhibitors of beta-amyloid protein production
EP0682526A4 (en) PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS.
BG105643A (en) Carboxylic acids and carboxylic acid isosteres of n-heterocycle compounds
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
HK1011972A1 (en) 3-(3,4-Dioxyphenyl)-pyrrolidines as type iv phosphodiesterase inhibitors for the treatment of inflammatory diseases
RU94046424A (en) Method of separation of dna-ase forms, human dna-ase, pharmaceutical composition, method of dna-ase storage, treatment method
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
DE69616792T2 (en) USE OF LEMELLARINE ALKALOIDS IN THERAPEUTIC PROCEDURES
ATE288761T1 (en) USE OF GLYCOSAMINOGLYCANS TO TREAT SENILE DEMENTIA
WO2003103573A3 (en) Methods for treating a neurological disorder by peripheral administration of a trophic factor
EP0319315A3 (en) The von willebrand factor binding domain of factor viii
WO2000071520A3 (en) Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
WO2002005798A3 (en) Pharmaceutical compositions for treating neurological disorders
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
EP0383171A3 (en) 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders
WO1999029640A3 (en) Compositions and methods for modulating the activity of fibroblast growth factor
WO1997014966B1 (en) Method of activating a novel ligand regulatory pathway
WO2001082954A3 (en) Ceruloplasmin and uses thereof in neurodegenerative related conditions
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA